Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The ACR’s Collaborative Initiatives Promote Awareness of Lupus, Rheumatic Diseases

Joan M. Von Feldt, MD, MSEd, FACR, FACP  |  July 11, 2016

When I began my tenure as ACR president this past November, I posited that it “takes a village” to grow and succeed in rheumatology’s rapidly changing environment. The ACR village includes volunteers who represent a diverse leadership pipeline reflecting the demographics of our younger members. It also includes the international rheumatology community that accounts for…

Dysbiosis of Gut, But Not Ocular Microbiome, Associated with Sjögren’s Syndrome

Lara C. Pullen, PhD  |  July 11, 2016

Research has explored the connection between Sjögren’s syndrome and intestinal dysbiosis associated with ocular mucosal disease. A recent study found that oral antibiotics and desiccating stress lead to extreme changes in the gut microbiota in mice. In patients with Sjögren’s syndrome, researchers found that patients with the most severe keratoconjunctivitis sicca and combined systemic and ocular disease had the lowest diversity of stool microbiota…

Why Rheumatologists Should Focus on Patients’ Cardiovascular Health

Simon M. Helfgott, MD  |  July 10, 2016

Baseball is a great sport. It’s fascinating to watch the evolving duel between pitcher and batter. As the former employs their remarkably powerful and versatile rotator cuff and forearm flexor muscles to hurl blazing pitches, the latter engages their exceptionally honed hand–eye neural link to make contact with the ball. Baseball is the ultimate summertime…

Prescription-Drug Monitoring Saves Lives, Could Save More

Ronnie Cohen  |  July 10, 2016

(Reuters Health)—State programs that monitor narcotic prescriptions help prevent 10 opioid-overdose deaths a day in the U.S., yet improvements could save another two people a day, a new study finds. States with the most robust programs—ones that tracked a greater number of potentially addictive medications and updated their databases at least weekly—saw the biggest drops…

U.S. Justice Department Has Concerns about Aetna-Humana Deal

Caroline Humer & Diane Bartz  |  July 9, 2016

(Reuters)—The U.S. Department of Justice has significant concerns about Aetna Inc.’s proposed acquisition of health insurer Humana Inc., a source familiar with the situation said on Thursday, and shares of Humana fell more than 11%. Aetna’s purchase of Humana would combine two of the largest providers of Medicare Advantage plans for elderly people, and investors…

FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira

Reuters Staff  |  July 8, 2016

(Reuters)—Amgen Inc’s biosimilar form of AbbVie Inc.’s adalimumab (Humira) arthritis drug, the world’s top-selling medicine, is similarly potent and safe as the original product, according to a preliminary review by staff members of the U.S. Food and Drug Administration (FDA). The assessment precedes an all-day meeting on Tuesday of an independent panel of medical advisers…

From the Expert: Enhance Your Teachable Moments to Attract Residents to Rheumatology

Richard Quinn  |  July 8, 2016

Attracting medical residents to rheumatology has been difficult. However, Eli Miloslavsky, MD, believes enhancing the teaching skills of rheumatology fellows, enabling them to push through barriers on the ward and leverage teachable moments with residents, may improve patient care and influence a resident’s choice of subspecialty…

Medicare Advantage Grows, but Provider Choice Is Limited

Mark Miller  |  July 7, 2016

CHICAGO (Reuters)—Medicare enrollees are moving in greater numbers than ever to the program’s managed care option as a way to save money. But the tradeoff is much less ability to use their preferred doctors and hospitals. Seniors can choose between traditional fee-for-service Medicare—which is accepted by most healthcare providers—or a Medicare Advantage plan. The latter…

White House Proposes Measures to Speed Genomic Test Development

Toni Clarke  |  July 7, 2016

WASHINGTON (Reuters)—The White House announced on Wednesday measures aimed at advancing President Barack Obama’s precision medicine initiative, including plans to speed the development of tests used to identify genetic mutations and guide medical treatment. The U.S. Food and Drug Administration said it planned to issue a proposal to create performance standards to guide development of…

U.S. Republicans Reject Democratic Funding Proposals for Opioids

Reuters Staff  |  July 7, 2016

WASHINGTON (Reuters) – Republican lawmakers in U.S. Congress on Wednesday rejected two Democratic amendments to provide nearly $1 billion in funding for bipartisan legislation intended to combat America’s opioid epidemic, aides said. The rejection, which came during a meeting of U.S. House of Representatives and Senate negotiators on the measure, could undermine Democratic support for…

  • « Previous Page
  • 1
  • …
  • 492
  • 493
  • 494
  • 495
  • 496
  • …
  • 814
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences